Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $33.00

Nurix Therapeutics (NASDAQ:NRIX) had its price target hoisted by Royal Bank Of Canada from $30.00 to $33.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price indicates a potential upside of 40.66% from the stock’s current price.

NRIX has been the topic of several other reports. Wells Fargo & Company downgraded Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their target price for the company from $28.00 to $25.00 in a report on Monday, June 8th. BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research note on Friday. Truist Financial increased their price target on Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Needham & Company LLC restated a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a report on Friday. Finally, Jefferies Financial Group lifted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.62.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $23.46 on Friday. The stock’s 50 day moving average price is $18.31 and its 200 day moving average price is $17.33. The company has a market cap of $2.43 billion, a PE ratio of -7.54 and a beta of 1.80. Nurix Therapeutics has a 1-year low of $8.19 and a 1-year high of $25.08.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The business had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. On average, equities research analysts anticipate that Nurix Therapeutics will post -2.88 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,051 shares of company stock worth $434,466 over the last three months. 6.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC increased its stake in shares of Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management bought a new position in shares of Nurix Therapeutics in the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in Nurix Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV purchased a new stake in Nurix Therapeutics in the 1st quarter worth $34,000. Finally, Wexford Capital LP bought a new position in Nurix Therapeutics during the third quarter valued at approximately $41,000.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix announced a global collaboration with Roche for bexobrutideg that could bring up to $2.3 billion in total payments, including a $700 million upfront payment, which is a major validation of the company’s pipeline and a meaningful source of non-dilutive capital. Article Title
• Positive Sentiment: Needham & Company LLC reaffirmed its Buy rating and set a $34 price target, implying notable upside from recent trading levels. Article Title
• Positive Sentiment: BTIG Research also reiterated a Buy rating with a $32 price target, reinforcing the view that the Roche deal and broader pipeline remain attractive to analysts. Article Title
• Neutral Sentiment: Nurix’s second-quarter results were weaker than expected, with a loss of $0.81 per share versus estimates for a $0.72 loss and revenue of $9.04 million versus $15.29 million expected, highlighting ongoing operating losses and revenue volatility. Article Title
• Neutral Sentiment: Additional coverage of the Q2 2026 earnings release echoed the same miss on EPS and revenue, which may temper enthusiasm but is partly offset by the Roche collaboration and analyst upgrades. Article Title

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.